Latest News

Claire Henchcliffe, MD, DPhil, an international leader in Parkinson disease research, reflects on mentorship, leadership development, and the systemic changes needed to support long-term success for women in neurology and clinical neuroscience.

In honor of National Women Physicians Day, held February 3, 2026, a trio of women clinicians highlighted the importance of individualized care for women living with multiple sclerosis.

Janis Miyasaki, MD, MEd, FRCPC, FAAN, a pioneer in neuropalliative care, provided clinical thoughts and perspectives on National Women Physicians Day and the ways to promote women leadership within the neurology field.

The FDA approves the FreedomEDGE infusion platform for rozanolixizumab, enhancing treatment options for generalized myasthenia gravis in clinical settings.

Here's some of what is coming soon to NeurologyLive® this week.

Anti–interleukin-6 receptor therapy may offer a new treatment option for patients with NMOSD and MOGAD who do not respond to rituximab, according to new findings.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the ACTRIMS and its history!

Neurocrine Biosciences launches a Phase 2 trial for NBI-1065890, targeting tardive dyskinesia with promising new treatment options.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 30, 2026.

Specifically, the alignment relates to a separate, planned clinical trial referred to as ASPIRE.

With regard to safety, there were no serious adverse events (AEs) or AEs of special interest deemed related to OCU410ST reported in the study.

A study of 614 brain donors revealed that individuals with stage III or IV CTE face the greatest risk of dementia.

New findings from the EMBARK study highlight Elevidys' significant long-term benefits in slowing Duchenne muscular dystrophy progression in young patients.